Autonomix Medical, Inc. Announces Closing of $11.2 Million in Gross Proceeds from Initial Public Offering
26 Enero 2024 - 3:05PM
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, today announced the
closing of its initial public offering of 2,234,222 shares of
common stock priced at $5.00 per share. The gross proceeds to
Autonomix, before deducting selling agent commissions and other
offering expenses payable by Autonomix were $11,171,110. Autonomix
expects its shares of common stock to begin trading on NASDAQ on
Monday, January 29, 2024 at approximately 10:30 AM
EST under the ticker symbol “AMIX.”
Digital Offering, LLC, acted as the lead
managing selling agent, along with R.F. Lafferty as syndicate
manager for the offering. Cambria Capital, LLC and DealMaker
Securities participated as selling group members. ArentFox Schiff
LLP acted as counsel to Autonomix and Bevilacqua PLLC acted as
counsel for the managing selling agent.
The offering was made only by means of an
offering circular. An offering statement on Form 1-A relating to
these securities has been filed with the U.S. Securities and
Exchange Commission (“SEC”) and has become qualified. A copy of the
final offering circular may be obtained from
https://www.sec.gov/Archives/edgar/data/1617867/000168316824000350/autonomix_1apos1.htm
This press release shall not constitute an offer
to sell, or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing our technology for
pancreatic cancer pain and pancreatitis pain, conditions that can
cause debilitating pain and need an effective solution. However,
our technology constitutes a platform with the potential to address
dozens of indications, including in cardiology, renal denervation
and chronic pain management across a wide disease spectrum.
For more information, visit autonomix.com and
connect with the Company on Twitter, LinkedIn and Facebook.
Forward Looking Statements
Some of the statements in this release are
“forward-looking statements,” which involve risks and
uncertainties. Forward-looking statements in this press release
include, without limitation, the timing of the trading of
Autonomix’s common stock on NASDAQ. Such forward-looking statements
can be identified by the use of words such as ‘’should,‘’ ‘’may,‘’
‘’intends,‘’ ‘’anticipates,‘’ ‘’believes,‘’ ‘’estimates,‘’
‘’projects,‘’ ‘’forecasts,‘’ ‘’expects,‘’ ‘’plans,‘’ and
‘’proposes.‘’
Although Autonomix Medical, Inc. (or Autonomix)
believes that the expectations reflected in these forward-looking
statements are based on reasonable assumptions, there are a number
of risks and uncertainties that could cause actual results to
differ materially from such forward-looking statements. You are
urged to carefully review and consider any cautionary statements
and other disclosures, including the statements made under the
heading “Risk Factors” and elsewhere in the offering statement
filed with the U.S. Securities and Exchange Commission (“SEC”).
Forward-looking statements speak only as of the date of the
document in which they are contained and Autonomix does not
undertake any duty to update any forward-looking statements except
as may be required by law.
Investor and Media ContactJTC Team, LLCJenene
Thomas833-475-8247autonomix@jtcir.com
Autonomix Medical (NASDAQ:AMIX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Autonomix Medical (NASDAQ:AMIX)
Gráfica de Acción Histórica
De May 2023 a May 2024